Investigational drug · Phase 2
HS-10566
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for High-risk Non-muscle-invasive Bladder Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "HS-10566"
First trial start
2026
Aug 5, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS-10566", any sponsor or status.
Conditions studied
As listed on its trial records.
- High-risk Non-muscle-invasive Bladder Cancer
Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "HS-10566" as an intervention, largest first.
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07468851 · 180 participants (planned) · Start Aug 5, 2026 · Primary completion Apr 30, 2028
Drug: HS-10566; HS-10566 and 1 more · For: High-risk Non-muscle-invasive Bladder Cancer
Sites: Beijing, China; Nanjing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for High-risk Non-muscle-invasive Bladder Cancer
- Cretostimogene GrenadenorepvecCG0070Phase 34 trials
CG Oncology, Inc. · Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer, Urologic Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.